PBPeera Buranakitjaroen

Peera Buranakitjaroen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peera Buranakitjaroen has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Role of dietary potassium and salt substitution in the prevention and management of hypertension

    by Yook-Chin Chia, Feng J. He, Maong-Hui Cheng, Jinho Shin, Hao-Min Cheng, Apichard Sukonthasarn, Tzung-Dau Wang, Minh Van Huynh, Peera Buranakitjaroen, Jorge Sison, et al.

    Cardiovascular diseases (CVD) continue to be the leading cause of deaths and disability worldwide and the major contributor is hypertension. Despite all the improvements in detecting hypertension together with technological advances and affordable, efficacious and relatively free of adverse effects anti-hypertensive agents, we continue to struggle to prevent the onset of hypertension and to control blood pressure (BP) to acceptable targets. The poor control of hypertension is commonly due to non-adherence to medications. Another reason is the failure to adopt diet and lifestyle changes. Reduction of dietary salt intake is important for lowering BP but the role of potassium intake is also important. Globally the intake of sodium is double that of the recommended 2 gm per day (equivalent to 5 gm of sodium chloride/salt) and half that of the daily recommended intake of potassium of 3500 mg/day, giving a sodium-to-potassium ratio of >1, when ideally it should be <1. Many studies have shown that a higher potassium intake is associated with lower BPs, particularly when coupled concurrently with a lower sodium intake giving a lower sodium to potassium ratio. Most hypertension guidelines, while recommending reduction of salt intake to a set target, do not specifically recommend a target for potassium intake nor potassium supplementation. Here we review the role of potassium and salt substitution with potassium in the management of hypertension. Hence, the focus of dietary changes to lower BP and improve BP control should not be on reduction of salt intake alone but more importantly should include an increase in potassium intake.


  • Open Access

    The HOPE Asia network 2022 up‐date consensus statement on morning hypertension management

    by Kazuomi Kario, Ji‐Guang Wang, Yook‐Chin Chia, Tzung‐Dau Wang, Yan Li, Saulat Siddique, Jinho Shin, Yuda Turana, Peera Buranakitjaroen, Chen‐Huan Chen, et al.

    Morning hypertension is an important clinical target in the management of hypertension for perfect 24‐h blood pressure (BP) control. Morning hypertension is generally categorized into two types: “morning surge” type and “sustained nocturnal and morning hypertension” type. The “morning surge” type is characterized by an exaggerated morning blood pressure surge (MBPS), and the “sustained nocturnal and morning hypertension” type with continuous hypertension from nighttime to morning (non‐dipper/riser type). They can be detected by home and ambulatory blood pressure measurements (HBPM and ABPM). These two forms of morning hypertension both increase the risk of cardiovascular and renal diseases, but may occur via different pathogenic mechanisms and are associated with different conditions. Morning hypertension should be treated to achieve a morning BP level of < 135/85 mmHg, regardless of the office BP. The second target morning BP levels is < 125/75 mmHg for high‐risk patients with morning hypertension and concomitant diseases. Morning hypertension is more frequently found in Asians, than in Westerners. Thus, the management of morning hypertension is especially important in Asia. The detection of morning hypertension and the individual home BP‐guided treatment approach targeting morning BP in combination with ABPM, and the optimal treatment of morning hypertension would reduce cardiovascular events in Asia.


  • Open Access

    Characteristics of hypertension in obstructive sleep apnea: An Asian experience

    by Satoshi Hoshide, Kazuomi Kario, Yook‐Chin Chia, Saulat Siddique, Peera Buranakitjaroen, Kelvin Tsoi, Jam Chin Tay, Yuda Turana, Chen‐Huan Chen, Hao‐Min Cheng, et al.

    Obstructive sleep apnea (OSA) is a risk of hypertension and is associated with cardiovascular disease (CVD) incidence. In Asian countries, the prevalence of OSA is high, as in Western countries. When blood pressure (BP) is evaluated in OSA individuals using ambulatory BP monitoring (ABPM), the BP phenotype often indicates abnormal BP variability, such as increased nighttime BP or abnormal diurnal BP variation, that is, non‐dipper pattern, riser pattern, and morning BP surge, and all these conditions have been associated with increased CVD events. Asians have a higher prevalence of increased nighttime BP or morning BP surge than Westerners. Therefore, this review paper focused on OSA and hypertension from an Asian perspective to investigate the importance of the association between OSA and hypertension in the Asian population. Such abnormal BP variability has been shown to be associated with progression of arterial stiffness, and this association could provoke a vicious cycle between abnormal BP phenotypes and arterial stiffness, a phenomenon recognized as systemic hemodynamic atherothrombotic syndrome (SHATS). OSA may be one of the background factors that augment SHATS. An oxygen‐triggered nocturnal oscillometric BP measurement device combined with a pulse oximeter for continuous SpO2 monitoring could detect BP variability caused by OSA. In addition to treating the OSA, accurate and reliable detection and treatment of any residual BP elevation and BP variability caused by OSA would be necessary to prevent CVD events. However, more detailed detection of BP variability, such as beat‐by‐beat BP monitoring, would further help to reduce CV events.


  • Open Access

    Comparison of guidelines for the management of hypertension: Similarities and differences between international and Asian countries; perspectives from HOPE‐Asia Network

    by Yook‐Chin Chia, Yuda Turana, Apichard Sukonthasarn, Yuqing Zhang, Jinho Shin, Hao‐Min Cheng, Jam Chin Tay, Kelvin Tsoi, Saulat Siddique, Narsingh Verma, et al.

    Guidelines on the management of hypertension have been developed by various professional bodies and institutions to primarily address the issues of diagnosis, treatment, and control in order to rationalize and improve the management of hypertension. Hypertension guidelines across the world have recently been updated following the new and controversial lower blood pressure threshold of ≥130/80 mmHg for the diagnosis of hypertension adopted by the Americans. While there are differences between the major as well as between the Asian national guidelines, there were also many similarities. This paper discusses and highlights the differences and similarities between the major international guidelines of the American College of Cardiology/American Heart Association, of the European Society of Cardiology/European Society of Hypertension, and of the International Society of Hypertension and also compares them with the Asian guidelines.


  • Open Access

    Office blood pressure measurement: A comprehensive review

    by Saulat Siddique, Aamir Hameed Khan, Hunaina Shahab, Yu‐Qing Zhang, Jam Chin Tay, Peera Buranakitjaroen, Yuda Turana, Narsingh Verma, Chen‐Huan Chen, Hao‐Min Cheng, et al.

    The conventional auscultatory methods for measuring blood pressure have been used to screen, diagnose, and manage hypertension since long. However, these have been found to be prone to errors especially the white coat phenomena which cause falsely high blood pressure readings. The Mercury sphygmomanometer and the Aneroid variety are no longer recommended by WHO for varying reasons. The Oscillometric devices are now recommended with preference for the Automated Office Blood Pressure measurement device which was found to have readings nearest to the Awake Ambulatory Blood Pressure readings. The downside for this device is the cost barrier. The alternative is to use the simple oscillometric device, which is much cheaper, with the rest and isolation criteria of the SPRINT study. This too may be difficult due to space constraints and the post‐clinic blood measurement is a new concept worth further exploration.


  • Open Access

    Guidance on ambulatory blood pressure monitoring: A statement from the HOPE Asia Network

    by Kazuomi Kario, Satoshi Hoshide, Yook‐Chin Chia, Peera Buranakitjaroen, Saulat Siddique, Jinho Shin, Yuda Turana, Sungha Park, Kelvin Tsoi, Chen‐Huan Chen, et al.

    Hypertension is an important public health issue due to its association with a number of serious diseases, including cardiovascular disease and stroke. The importance of evaluating hypertension taking into account different blood pressure (BP) profiles and BP variability (BPV) is increasingly being recognized, and is particularly relevant in Asian populations given the specific features of hypertension in the region (including greater salt sensitivity and a high rate of nocturnal hypertension). Ambulatory BP monitoring (ABPM) is the gold standard for diagnosing hypertension and assessing 24‐hour BP and provides data on several important parameters that cannot be obtained using any other form of BP measurement. In addition, ABPM parameters provide better information on cardio‐ and cerebrovascular risk than office BP. ABPM should be used in all patients with elevated BP, particularly those with unstable office or home BP, or who are suspected to have white‐coat or masked hypertension. ABPM is also an important part of hypertension diagnosis and monitoring in high‐risk patients. ABPM needs to be performed using a validated device and good practice techniques, and has a role both in hypertension diagnosis and in monitoring the response to antihypertensive therapy to ensure strict BP control throughout the 24‐hour period. Use of ABPM in clinical practice may be limited by cost and accessibility, and practical education of physicians and patients is essential. The ABPM evidence and practice points in this document are based on the Hypertension Cardiovascular Outcome Prevention and Evidence (HOPE) Asia Network expert panel consensus recommendations for ABPM in Asia.


  • Open Access

    Effects of Four Noble Truths Practice on Hypertension Control

    by Sadudee Rojanapirom, Siriorn Sindhu, Ketsarin Utriyaprasit, Peera Buranakitjaroen, Chukiat Viwatwongkasem

    Objective: To examine the effects of Four Noble Truths practice in controlling blood pressure with three-group comparison, involving a Mobile Web group, Guidebook group and usual care group in patients with stage 1 hypertension.Methods: This randomized controlled trial was conducted in one university hospital setting. 145 participants were recruited into the study by randomized selection and were randomly assigning to the three groups. Of these, 45 participated as Mobile Web users, 50 as Guidebook users and 50 in the control group. The Mobile Web and Guidebook were developed using the guidance of the Four Noble Truths and received a phone call every two weeks for three times while control received a usual care. Then, the outcomes were measured including blood pressure and satisfaction at two-month after recruitment. The average blood pressure and satisfaction were compared by comparative descriptive statistic. Finally, analysis of covariance (ANCOVA) was used to analyze the covariate that may influence the outcomes with the post hoc analysis by Bonferroni. Results: Participants who received Mobile Web and Guidebook had reduced their blood pressure more than those receiving usual care, with statistical significance (P < 0.05). It was found that blood pressures could be lowered to a maximum level of 5.09 ± 9.62mmHg within 8 weeks of treatment. Altogether, both groups were satisfied with healthcare services more than those receiving usual care, with statistical significance (P < 0.05).Conclusion: The program could be applied to control high blood pressure in patients with stage 1 hypertension. The outstanding of this program could support overall difference in healthcare of each patient with fast efficacy.

  • An overview of hypertension and cardiac involvement in Asia: Focus on heart failure

    by Arieska Ann Soenarta, Peera Buranakitjaroen, Yook‐Chin Chia, Chen‐Huan Chen, Jennifer Nailes, Satoshi Hoshide, Huynh Van Minh, Sungha Park, Jinho Shin, Saulat Siddique, et al.

    Cardiovascular Disease (CVD) is the leading cause of deaths worldwide, contributing to about 30% of all deaths. Half of the cases of CVD are estimated in Asia, the world's most populous continent. Hypertension, a major modifiable risk factor for CVD, results in more deaths than any other CV risk factors in the Asian regions. The total number of patients with hypertension is likely to grow as the population ages. The proportion of the elderly population aged 65 years or more in Asia is expected to increase from 7.4% in 2015 to 10.9% in 2030. It is important to note that more than half (54%) of the world's population live in Asia. Aside of being the biggest single risk factor for global deaths, hypertension is also an important precursor and most common risk factor of heart failure (HF). An increase in HF prevalence is clearly related to the rapid epidemiological transition caused by changes in lifestyle in Asian countries. However, the availability of data on HF burden and health care delivery is limited in Asia compared with Europe and North America. This reality has driven the working group of Asian experts for example the HOPE Asia Network to concentrate on hypertension as risk factors for CVD, with the mission to improve the management of hypertension resulting in organ protection toward a goal of achieving “ZERO” CV event in Asia. This paper aims to give an overview regarding the heart problems caused by hypertension in Asia, focus on HF.


  • Open Access

    Comparison of day‐to‐day blood pressure variability in hypertensive patients with type 2 diabetes mellitus to those without diabetes: Asia BP@Home Study

    by Yook‐Chin Chia, Kazuomi Kario, Naoko Tomitani, Sungha Park, Jinho Shin, Yuda Turana, Jam Chin Tay, Peera Buranakitjaroen, Chen‐Huan Chen, Satoshi Hoshide, et al.

    Blood pressure variability (BPV) has been shown to be independently associated with cardiovascular (CV) mortality and morbidity. Patients with type 2 diabetes mellitus (T2DM) have also been shown to have increased BPV. We aimed to compare BPV in hypertensive patients with diabetes with those without diabetes. A total of 1443 hypertensive patients measured their blood pressure (BP) twice in the morning and twice before bed at home for a week. Demographic data, history of T2DM, and anti‐hypertensive use were captured. Clinic BP was measured twice in the clinic. Control of BP was defined as clinic systolic BP (SBP) P = .188). However, the mean morning home SBP was significantly higher and control rate lower in hypertensives with diabetes than those without (132.3 ± 15 mm Hg vs 129.7 ± 14.4 mm Hg P = .005, 39.4% vs 47.6% P = .007), respectively. Masked uncontrolled morning hypertension was higher in those with diabetes versus those without (12.8% vs 8.4%, respectively). There was no statistically significant difference in BPV between those with and without diabetes. In summary, clinic SBP was similar in hypertensives with or without diabetes. However, control of BP based on both clinic and home SBP thresholds was poorer in hypertensives with diabetes compared to those without. Masked uncontrolled morning hypertension was higher in those with diabetes than those without. There was no difference in BPV between the two groups.


  • Open Access

    The influence of the ambient temperature on blood pressure and how it will affect the epidemiology of hypertension in Asia

    by Sungha Park, Kazuomi Kario, Yook‐Chin Chia, Yuda Turana, Chen‐Huan Chen, Peera Buranakitjaroen, Jennifer Nailes, Satoshi Hoshide, Saulat Siddique, Jorge Sison, et al.

    Epidemiologic studies have consistently demonstrated an increased risk of cardiovascular disease during colder temperatures. Hemodynamic changes associated with cold temperature and an increase in thrombogenicity may both account for the increase in cardiovascular risk and mortality. Studies using both in‐office and out‐of‐office BP measurements have consistently shown an elevation in BP during the colder seasons. The large difference in BP between cold and warm months may increase the incidence of hypertension and reduce the hypertension control rate, potentially resulting in increased cardiovascular risk, especially among those at risk of cardiovascular disease. The current trends in global warming and climate change may have a profound impact on the epidemiology of hypertension and cardiovascular disease, as changes in the climate may significantly affect both BP variability and cardiovascular disease, especially in those with high cardiovascular risk and the elderly. Furthermore, climate change could have a significant influence on hypertension in Asia, considering the unique characteristics of hypertensive patients in Asia. As an increase in ambient temperature decreases the mean daytime average and morning surge in BP, but increases the nocturnal BP, it is difficult to predict how environmental changes will affect the epidemiology and prognosis of hypertension in the Asian‐Pacific region. However, these seasonal variations in BP could be minimized by adjusting the housing conditions and using anticipation medicine. In this review, we discuss the impact of seasonal variation in the ambient temperature on hypertension and cardiovascular disease and discuss how this may impact the epidemiology of hypertension and cardiovascular disease.